Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07484971

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.

It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Prostate Cancer Adenocarcinoma Carcinoma Disease Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Pathologic Processes Pathological Conditions, Signs and Symptoms Prostate Cancer (Adenocarcinoma) Prostate Cancer (Diagnosis) Prostate Cancer (Post Prostatectomy) Prostate Cancer Metastatic Prostate Cancer Patients Treated by Radiotherapy Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

19 year and older

Sex eligibility

Male

Study type

Observational

Primary location

CAC Adrar - Oncology Department, Adrar, Algeria

Loading trial locations.

About this study

This is a descriptive, cross-sectional clinical study including patients with histologically and/or biologically confirmed prostate cancer who are being followed in the participating centers. This study planned to enroll 500 patients.

Data will be collected from medical records and structured patient interviews (≈30 minutes). A standardized electronic case report form (eCRF) will be used to ensure completeness and reliability of the data. The variables studied will include sociodemographic data, medical history, clinical and biological characteristics of the disease, diagnostic examinations performed, and the therapeutic strategies implemented. All information will be anonymized and used exclusively for research purposes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 19 years and older.
  • Diagnosis of prostate cancer confirmed histologically and/or biologically.
  • Patients followed in the participating oncology departments.
  • Written informed consent obtained.

Non Inclusion Criteria:

  • Histological types other than carcinoma
  • Secondary tumors
  • Participation in an interventional study

Treatment and study plan

Primary outcomes

  1. Socio-demographic characteristics of patients with prostate cancer in Algeria

    Time frame: At Baseline ( Initial visit )

    Frequency (%) of sociodemographic characteristics of patients with prostate cancer in Algeria, including age at diagnosis, marital status, and socioeconomic level.

  2. Personal and family history of cancer

    Time frame: At Baseline (Initial Visit)

    Frequency (%) of patients with personal and family history of cancer.

  3. Environmental and occupational exposures

    Time frame: At Baseline (Initial visit)

    Frequency (%) of patients with environmental or occupational exposures.

  4. Smoking history

    Time frame: At Baseline (Initial visit)

    Frequency (%) of patients according to smoking status (current, former, never).

  5. Alcohol consumption

    Time frame: At Baseline (Initial visit)

    Frequency (%) of patients according to alcohol consumption (yes/no).

  6. Initial symptoms and circumstances of diagnosis

    Time frame: At Baseline (Initial visit)

    Frequency (%) of patients according to type of initial symptoms and circumstances of diagnosis.

  7. International Prostate Symptom Score (IPSS)

    Time frame: At Baseline (Initial visit)

    Distribution of patients according to the International Prostate Symptom Score (IPSS) at baseline. The IPSS is a validated questionnaire assessing the severity of lower urinary tract symptoms, with a total score ranging from 0 to 35, where higher scores indicate more severe (worse) symptoms.

  8. Evolutionary status of patients

    Time frame: At Baseline (Initial visit)

    Frequency (%) of patients according to disease status (in remission or with disease progression).

Secondary outcomes

  1. Diagnosis by PSA testing

    Time frame: At Baseline (Initial visit)

    % of patients diagnosed by PSA testing.

  2. Diagnosis by imaging

    Time frame: At Baseline (Initial visit)

    % of patients diagnosed by imaging.

  3. Diagnosis by biopsy

    Time frame: At Baseline (Initial visit)

    % of patients diagnosed by biopsy.

  4. Time from symptom onset to first medical consultation

    Time frame: At Baseline (Initial visit)

    Median time (in days) between onset of first symptoms and first medical consultation.

  5. Time from first consultation to confirmed diagnosis

    Time frame: At Baseline (Initial visit)

    Median time (in days) between first medical consultation and confirmed diagnosis.

  6. Patients discussed in multidisciplinary team meetings

    Time frame: At Baseline (Initial visit)

    % of patients discussed in tumor boards / multidisciplinary team meetings.

  7. Initial treatment: Surgery

    Time frame: At Baseline (Initial visit)

    % of patients receiving surgery as initial treatment.

  8. Initial treatment: Radiotherapy

    Time frame: At Baseline (Initial visit)

    % of patients receiving radiotherapy as initial treatment.

  9. Initial treatment: Hormone therapy

    Time frame: At Baseline (Initial visit)

    % of patients receiving hormone therapy as initial treatment.

  10. Initial treatment: Active surveillance

    Time frame: At Baseline (Initial visit)

    % of patients under active surveillance as initial management.

  11. Time from diagnosis to treatment initiation

    Time frame: At Baseline (Initial visit)

    Median time (in days) between diagnosis and treatment initiation.

  12. Specialty of physician initiating treatment

    Time frame: At Baseline (Initial visit)

    Medical specialty of the physician initiating treatment (urologist, oncologist, etc.).

  13. Adverse events

    Time frame: At Baseline (Initial visit)

    Frequency of adverse events by system/organ class and distribution according to severity grades (CTCAE grades 1 to 5).

Study contacts

Contact information is provided by the study sponsor or research team.

BOUNEDJAR ADDA, Professor

CONTACT

[email protected]

+213 25 20 90 72

Sponsors and collaborators

Lead sponsor

Société Algérienne de Formation et Recherche en Oncologie

Other

Collaborators

  • Astellas Pharma Inc
  • ES Clinical Research
  • Ipsen

Registry information

Acronym: CLIQQC

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 20, 2026
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.